GlycoMimetics Inc. | Mutual Funds
Mutual Funds that own GlycoMimetics Inc.
SPDR S&P Biotech ETF
1,479,281
3.44%
3,807
0.37%
09/06/2018
FTIF SICAV - Franklin Biotechnology Discovery Fund
1,338,479
3.11%
55,500
0.85%
06/30/2018
Oppenheimer Global Fund
1,315,880
3.06%
1,315,880
0.17%
03/31/2018
Fidelity Select Health Care Portfolio
1,120,000
2.6%
0
0.22%
07/31/2018
Prudential Jennison Health Sciences Fund
1,028,787
2.39%
0
0.59%
07/31/2018
T Rowe Price Health Sciences Fund
980,715
2.27%
980,715
0.11%
06/30/2018
Polar Capital Funds Plc - Healthcare Opportunities Fund
967,061
2.25%
-5,554
0.81%
07/31/2018
T Rowe Price New Horizons Fund
947,248
2.2%
190,200
0.06%
06/30/2018
Franklin Biotechnology Discovery Fund
825,200
1.92%
155,100
0.83%
03/31/2018
Vanguard Total Stock Market Index Fund
812,815
1.89%
0
0%
07/31/2018
| Address |
9708 Medical Center Drive
Rockville Maryland 20850
United States
|
|
Employees
|
- |
| Website |
http://www.glycomimetics.com |
| Updated |
07/08/2019 |
| GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. |
